Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Beigene Ltd ADR (NQ: BGNE )

205.04 -0.43 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
From BeiGene
Via Business Wire
Why Are BeiGene Shares Trading Lower Today
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to  
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in Wednesday Morning Trading
Via Investor Brand Network
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
From BeiGene
Via Business Wire
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
From BeiGene
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's Happening With Beigene Shares During Wednesday's Session
Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness. 
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks. 
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical... 
Via Benzinga
BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
From The Rosen Law Firm PA
Via GlobeNewswire
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)
From Kirby McInerney LLP
Via Business Wire
BGNE LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
From The Rosen Law Firm, P.A.
Via Business Wire
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics  
Via Benzinga
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
From BeiGene
Via Business Wire
Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading. 
Via Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
From BeiGene
Via Business Wire
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
From BeiGene
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.